Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:TARS NASDAQ:TECX NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.36+0.2%$33.90$22.24▼$46.00$2.16B0.541.16 million shs890,007 shsTARSTarsus Pharmaceuticals$58.66+0.1%$61.54$38.51▼$85.25$2.52B0.51.52 million shs446,508 shsTECXTectonic Therapeutic$30.37-3.9%$31.21$14.39▼$39.53$573.05M3.21215,484 shs99,105 shsTRVITrevi Therapeutics$17.53+2.0%$16.11$6.55▼$20.22$2.44B13.01 million shs1.65 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.22%-8.20%+0.22%+43.60%-10.36%TARSTarsus Pharmaceuticals+0.14%-1.99%-12.59%-4.54%+38.94%TECXTectonic Therapeutic-3.92%-6.84%-1.14%+6.41%+32.50%TRVITrevi Therapeutics+2.04%-8.08%+0.60%+21.65%+122.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.36+0.2%$33.90$22.24▼$46.00$2.16B0.541.16 million shs890,007 shsTARSTarsus Pharmaceuticals$58.66+0.1%$61.54$38.51▼$85.25$2.52B0.51.52 million shs446,508 shsTECXTectonic Therapeutic$30.37-3.9%$31.21$14.39▼$39.53$573.05M3.21215,484 shs99,105 shsTRVITrevi Therapeutics$17.53+2.0%$16.11$6.55▼$20.22$2.44B13.01 million shs1.65 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+0.22%-8.20%+0.22%+43.60%-10.36%TARSTarsus Pharmaceuticals+0.14%-1.99%-12.59%-4.54%+38.94%TECXTectonic Therapeutic-3.92%-6.84%-1.14%+6.41%+32.50%TRVITrevi Therapeutics+2.04%-8.08%+0.60%+21.65%+122.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$42.7817.65% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.5054.28% UpsideTECXTectonic Therapeutic 2.75Moderate Buy$79.40161.44% UpsideTRVITrevi Therapeutics 3.00Buy$24.9142.09% UpsideCurrent Analyst Ratings BreakdownLatest TECX, TARS, AGIO, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026TARSTarsus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $89.007/21/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$54.00 ➝ $52.007/20/2026TRVITrevi Therapeutics BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$36.007/20/2026TECXTectonic Therapeutic Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/20/2026TRVITrevi Therapeutics BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/20/2026TRVITrevi Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $31.007/20/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.007/17/2026TARSTarsus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026TRVITrevi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M40.02N/AN/A$20.46 per share1.78TARSTarsus Pharmaceuticals$535.08M4.72N/AN/A$8.09 per share7.25TECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.14N/A23.09N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)Latest TECX, TARS, AGIO, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026TARSTarsus Pharmaceuticals-$0.21N/AN/AN/A$169.11 millionN/A8/6/2026Q2 2026TECXTectonic Therapeutic-$1.3488N/AN/AN/AN/AN/A8/6/2026Q2 2026TRVITrevi Therapeutics-$0.11N/AN/AN/AN/AN/A7/30/2026Q2 2026AGIOAgios Pharmaceuticals-$1.6588N/AN/AN/A$26.07 millionN/A5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/A5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59TARSTarsus Pharmaceuticals0.213.743.71TECXTectonic TherapeuticN/A18.5118.51TRVITrevi TherapeuticsN/A24.7524.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ATARSTarsus Pharmaceuticals90.01%TECXTectonic Therapeutic62.63%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%TARSTarsus Pharmaceuticals9.64%TECXTectonic Therapeutic39.80%TRVITrevi Therapeutics15.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/ATRVITrevi Therapeutics20141.98 million120.13 millionOptionableTECX, TARS, AGIO, and TRVI HeadlinesRecent News About These CompaniesAffinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVIJuly 25 at 3:04 AM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenJuly 25 at 1:30 AM | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"July 25 at 1:29 AM | marketbeat.comSiren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVIJuly 24 at 6:16 AM | marketbeat.comFifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVIJuly 24 at 3:32 AM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital MarketsJuly 22 at 5:41 AM | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, B. Riley Financial Analyst SaysJuly 22 at 1:24 AM | americanbankingnews.comHC Wainwright Increases Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00July 22 at 1:24 AM | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's WhyJuly 20, 2026 | marketbeat.comB. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock PriceJuly 20, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock PriceJuly 20, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Here's WhyJuly 18, 2026 | marketbeat.comTrevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable MarketJuly 17, 2026 | insidermonkey.comTrevi climbs after late-stage trial setback for GSK cough therapyJuly 17, 2026 | msn.comWhy Trevi Therapeutics, Inc.’s (TRVI) Stock Is Up 10.08%July 17, 2026 | aaii.comATrevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Should You Buy?July 17, 2026 | marketbeat.comStock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)July 15, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading Up 7.4% - What's Next?July 14, 2026 | marketbeat.comCandriam S.C.A. Purchases Shares of 773,620 Trevi Therapeutics, Inc. $TRVIJuly 13, 2026 | marketbeat.comSG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVIJuly 10, 2026 | marketbeat.comTrevi Therapeutics Inc TRVIJune 23, 2026 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTECX, TARS, AGIO, and TRVI Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$36.36 +0.08 (+0.22%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$36.33 -0.03 (-0.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$58.66 +0.08 (+0.14%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$58.52 -0.13 (-0.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Tectonic Therapeutic NASDAQ:TECX$30.37 -1.24 (-3.92%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$30.36 -0.01 (-0.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Trevi Therapeutics NASDAQ:TRVI$17.53 +0.35 (+2.04%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$17.60 +0.07 (+0.40%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
